Thank you to those who shared your ITP experiences through our online survey, and thanks to GlaxoSmithKline for funding and developing the questionnaire. Download PDF

A total of 1,002 ITP patients and 1,031 age and gender-matched controls answered questions from three standard quality-of-life questionnaires plus additional questions in a survey funded by Amgen. Selected results were published in three journal articles. Below are links to the abstracts. Contact PDSA for copies of the articles.

• “Impact of ITP on physician visits and workplace productivity.”
   View Abstract
  
  
• “Health-related quality of life of immune thrombocytopenic purpura patients: results from a web-based survey.”
   View Abstract
  
  
• “Impact of corticosteroid-related symptoms in patients with immune thrombocytopenic purpura: results of a survey of 985 patients.”
   View Abstract

Introduction

From August 2001 through December 2001, we collected 916 responses from our Survey of Non-traditional Treatments of ITP.  This survey was created by James Bussel, MD of the Weill Medical Center of Cornell University and the staff of the Platelet Disorder Support Association (PDSA) and placed on the PDSA website to gather replies.

Note: In the survey, the term 'non-traditional' is synonymous with 'complementary.'  The survey also collected data on 'traditional' (conventional) therapies for comparison.

(Since these results are from a web-based survey, there is no medical validation of the results. For advice on your unique medical condition, please consult your health care provider. No portion of these results may be reproduced without express written consent of PDSA.)